Results 171 to 180 of about 173,276 (306)

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

The left ventricular end-diastolic pressure index predicts outcomes in patients with left ventricular diastolic dysfunction

open access: yesPolish Archives of Internal Medicine, 2023
Liangjie, Xu   +5 more
openaire   +2 more sources

Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI

open access: yesiNew Medicine, EarlyView.
Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang   +9 more
wiley   +1 more source

Comparative diagnostic accuracy study of point of care ultrasound techniques for detection of left atrial enlargement by hospital medicine physicians from archived echocardiogram images

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background Left atrial enlargement (LAE) is predictive of cardiovascular morbidity and mortality. Prior studies of point‐of‐care ultrasound (POCUS) interpretation methods for identifying LAE utilized older echocardiographic reference ranges. Objectives Compare the test characteristics of hospitalist‐performed POCUS techniques for identifying ...
Christopher J. Smith   +7 more
wiley   +1 more source

MiR‐145‐5p Attenuates Doxorubicin‐Induced Heart Injury Through Targeting Cardiomyocyte Pyroptosis

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Doxorubicin (DOX), a potent anthracycline chemotherapeutic, exhibits dose‐dependent cardiotoxicity that limits its clinical utility. Although miR‐145‐5p demonstrates cardioprotective properties in cardiovascular diseases, its role in DOX‐induced cardiomyopathy remains undefined.
Xing‐Tao Chen   +4 more
wiley   +1 more source

Diagnostic implication of left atrial stiffness index in patients with SLE with left ventricular diastolic dysfunction. [PDF]

open access: yesLupus Sci Med
Zhong X   +13 more
europepmc   +1 more source

Atrial cardiomyopathy

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy